Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

COVID-19 vaccine programmes are expected to cost poorer countries an additional 56.6% on health budgets, compared with just 0.8% on wealthy countries’ health expenditure, according to new data from the United Nations Development Programme (UNDP), the World Health Organisation (WHO) and the University of Oxford.

Vaccine being administrered

According to the research, inequity will have a 'lasting and profound impact' on socio-economic recovery in low and lower-middle income countries unless there is urgent action to make vaccines affordable and accessible to everyone.

With the current cost of vaccines calculated at an average US$15.80, and without immediate global financial support, low-income countries are forecast to see health costs soar by more than half, to vaccinate fully a target of 70% of their populations. But high-income countries would have to increase spending by just 0.8 percent to achieve the same results. This would account for half of low-income countries' projected GDP growth in 2021, against 0.2% for high-income countries.

These insights come from the Global Dashboard on Vaccine Equity , a joint initiative from UNDP, WHO and Oxford’s Blavatnik School of Government, which combines the latest COVID-19 vaccination information with the most recent socio-economic data. It illustrates why vaccine equity is not only critical to saving lives but also to driving a fairer and faster recovery from the pandemic.

Read the full story on the University of Oxford website.

Similar stories

Drug could help diabetic hearts recover after heart attack - Oxford research

Researchers at the University of Oxford have identified a drug that could ultimately help improve heart function in people with diabetes who have heart attacks.

Largest ever global study of tuberculosis identifies genetic causes of drug resistance

Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis (TB) drug treatments.

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.